This is from February 2026 and notably there’s no way for the public to try out the model, nor is it published in a peer-reviewed journal
"In November 2024, preliminary results of CASP16 showed AlphaFold 3-based models did not significantly outperform older methods for predicting protein-ligand interactions. The top performing models in the CASP16 Pose Prediction for Pharma Targets section were ClusPro[13] and CoDock[14] utilizing AlphaFold 2 based predictions, human visual inspection, and manual adjustments.[15]<p>In April 2025 Isomorphic Labs raised $600 Million in its first ever external funding round, led by Thrive Capital.[16][17]"<p><a href="https://en.wikipedia.org/wiki/Isomorphic_Labs" rel="nofollow">https://en.wikipedia.org/wiki/Isomorphic_Labs</a>
What technical advancement made this possible? The text is vague about this.
This is old news.
Would like more details technically on their approach. Is it a neuro-symbolic approach, do they do something beyond just scaling, or some other architecture breakthrough, but alas drug discovery must remain proprietary. Thank gods for capitalism!